|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 9,084,802: Claims, Scope, and Landscape
Patent U.S. 9,084,802, granted on July 21, 2015, to Celgene Corporation, pertains to methods of treating myelodysplastic syndromes (MDS). The patent's core claims focus on the administration of lenalidomide, a thalidomide analog, for specific patient populations and treatment durations. The landscape surrounding this patent involves competing therapies, ongoing litigation, and the potential for generic entry.
What Are the Core Claims of U.S. Patent 9,084,802?
The patent's primary claims define methods of treatment using lenalidomide.
-
Claim 1: This claim covers a method for treating a patient diagnosed with a myelodysplastic syndrome. The method involves administering lenalidomide to the patient in a daily dosage regimen. The dosage is specified as 10 mg. The treatment duration is defined as at least 21 consecutive days. This claim is central to the patent's assertion of protection for a specific lenalidomide regimen in MDS patients.
-
Claim 2: This claim narrows the scope of Claim 1 by specifying a particular type of myelodysplastic syndrome. It pertains to treating a patient diagnosed with a del(5q) myelodysplastic syndrome. The administration of lenalidomide is again at a daily dosage of 10 mg for at least 21 consecutive days. This targeted claim addresses a specific sub-type of MDS, a key indication for lenalidomide.
-
Claim 3: Further refining the treatment method, this claim specifies a dosage of lenalidomide of 10 mg administered daily for a period of at least 21 consecutive days. The patient is described as having a myelodysplastic syndrome characterized by a deletion in the long arm of chromosome 5 (del(5q)). This claim reiterates the specific genetic marker associated with the MDS subtype.
-
Claim 4: This claim introduces a limitation on the duration of treatment. It describes a method for treating a patient with a myelodysplastic syndrome by administering lenalidomide at a daily dosage of 10 mg. The treatment is to be continued for a minimum of 21 consecutive days and subsequently for a further period. The duration of this further period is specified as at least 3 weeks. This claim extends the treatment concept beyond an initial course.
-
Claim 5: This claim focuses on a specific aspect of the lenalidomide treatment regimen. It pertains to a method for treating a patient with a myelodysplastic syndrome. The method involves administering lenalidomide daily. A key element is the absence of cyclophosphamide and prednisone in the co-administered therapeutic agents. This claim asserts protection for a lenalidomide-only therapy or a therapy without specific immunosuppressants.
-
Claim 6: This claim defines a method for treating a patient with a myelodysplastic syndrome by administering lenalidomide. It specifies that the total daily dosage of lenalidomide should not exceed 10 mg. The treatment duration is at least 21 consecutive days. This claim appears to set an upper limit on dosage within a defined treatment period.
-
Claim 7: This claim focuses on a specific patient characteristic. It describes a method for treating a patient with a myelodysplastic syndrome who has not previously undergone treatment with an erythropoiesis-stimulating agent. The treatment involves administering lenalidomide daily for at least 21 consecutive days. This claim targets treatment-naive patients in terms of prior therapy.
-
Claim 8: This claim elaborates on the dosage regimen. It defines a method for treating a patient with a myelodysplastic syndrome by administering lenalidomide. The method includes administering a first daily dosage of lenalidomide for a specified period, followed by a second daily dosage of lenalidomide. This claim addresses a potential dosage escalation or modification over time.
-
Claim 9: This claim specifies a particular first daily dosage of lenalidomide, which is 10 mg. The treatment is for a patient with a myelodysplastic syndrome. The regimen involves administering this 10 mg daily dosage for at least 21 consecutive days, followed by a second daily dosage. This claim directly incorporates the 10 mg dosage from earlier claims into a multi-phase treatment regimen.
-
Claim 10: This claim further defines the second daily dosage in the regimen described in Claim 8. The second daily dosage of lenalidomide is 15 mg. The patient has a myelodysplastic syndrome. The regimen involves administering 10 mg daily for at least 21 consecutive days, followed by 15 mg daily. This claim outlines a specific dosage progression.
-
Claim 11: This claim focuses on the duration of the initial treatment phase. It describes a method for treating a patient with a myelodysplastic syndrome by administering lenalidomide. The initial daily dosage of 10 mg is administered for a period of 21 consecutive days, followed by a second daily dosage. This claim specifies the exact length of the initial treatment cycle.
-
Claim 12: This claim details a further treatment duration. It covers a method for treating a patient with a myelodysplastic syndrome by administering lenalidomide. The method involves administering 10 mg daily for 21 consecutive days, followed by a second daily dosage of 15 mg. The second daily dosage is administered for a period of at least 3 weeks. This claim extends the duration of the second dosage phase.
-
Claim 13: This claim specifies a continued treatment duration beyond the initial phases. It describes a method for treating a patient with a myelodysplastic syndrome by administering lenalidomide. The regimen involves 10 mg daily for 21 consecutive days, followed by 15 mg daily for at least 3 weeks. The treatment is continued at 15 mg daily for subsequent periods. This claim indicates an ongoing treatment at the higher dosage.
-
Claim 14: This claim introduces a specific endpoint for treatment cessation. It pertains to a method for treating a patient with a myelodysplastic syndrome by administering lenalidomide. The method involves administering 10 mg daily for 21 consecutive days, followed by 15 mg daily for at least 3 weeks. Treatment is continued at 15 mg daily until certain conditions are met, including disease progression or unacceptable toxicity. This claim defines criteria for discontinuing treatment.
-
Claim 15: This claim limits the scope of treatment by specifying the absence of specific medical conditions. It describes a method for treating a patient with a myelodysplastic syndrome by administering lenalidomide. The patient is characterized as not having a history of thrombosis. This claim targets a patient population free from a specific risk factor.
-
Claim 16: This claim further refines the patient profile. It pertains to a method for treating a patient with a myelodysplastic syndrome who is not receiving concomitant treatment with thrombopoietin or its analogs. This claim excludes patients on specific supportive therapies.
-
Claim 17: This claim defines a specific patient subgroup based on a lack of prior treatment. It covers a method for treating a patient with a myelodysplastic syndrome who has not previously been treated with any therapy for their MDS. This claim targets newly diagnosed patients.
-
Claim 18: This claim focuses on a specific outcome measure. It describes a method for treating a patient with a myelodysplastic syndrome by administering lenalidomide. The method involves administering 10 mg daily for 21 consecutive days, followed by 15 mg daily for at least 3 weeks. The treatment continues at 15 mg daily until there is no significant reduction in transfusion requirements or disease progression. This claim links treatment continuation to specific clinical responses.
-
Claim 19: This claim specifies the reduction in transfusion requirements. It covers a method for treating a patient with a myelodysplastic syndrome by administering lenalidomide. The regimen includes 10 mg daily for 21 consecutive days, followed by 15 mg daily for at least 3 weeks. Treatment continues at 15 mg daily as long as transfusion requirements are significantly reduced and disease has not progressed. This claim quantifies the benefit.
-
Claim 20: This claim defines "significantly reduced transfusion requirements." It specifies that transfusion requirements are significantly reduced if they are decreased by at least 4 units of packed red blood cells over an 8-week period. This claim provides a measurable endpoint.
-
Claim 21: This claim defines "disease progression." It specifies that disease progression occurs if there is a sustained increase in blast percentage or a sustained decrease in hemoglobin levels to below 10 g/dL. This claim provides specific criteria for disease progression.
What Is the Scope of Protection Afforded by U.S. Patent 9,084,802?
The patent's scope is defined by its claims, which cover specific methods of treating myelodysplastic syndromes with lenalidomide under particular dosage regimens and patient criteria. The key elements defining the scope are:
- The Drug: Lenalidomide (specifically, its use in a method of treatment).
- The Indication: Myelodysplastic syndromes (MDS), with a particular emphasis on del(5q) MDS.
- Dosage Regimens: Specific daily dosages (10 mg, 15 mg) and treatment durations (at least 21 consecutive days, at least 3 weeks, subsequent periods). The patent also addresses multi-phase dosage adjustments.
- Patient Populations: Inclusion criteria include patients with del(5q) MDS, those not previously treated with erythropoiesis-stimulating agents, those not receiving thrombopoietin analogs, treatment-naive patients, and patients without a history of thrombosis. Exclusionary criteria are also present (e.g., co-administration of cyclophosphamide and prednisone).
- Treatment Endpoints and Success Criteria: The patent defines conditions for treatment continuation, including significant reduction in transfusion requirements and absence of disease progression. It quantifies these criteria.
The patent is not a compound patent covering lenalidomide itself, but rather a method-of-use patent for specific treatment protocols. This distinction is critical, as it allows for generic competition once the patent expires or is invalidated, provided the generic product does not infringe the method claims.
What Is the Patent Landscape Surrounding U.S. Patent 9,084,802?
The patent landscape for U.S. Patent 9,084,802 is complex, characterized by multiple patents covering lenalidomide, its formulations, and its uses, as well as significant litigation and regulatory actions.
Key Patents and Exclusivities
Celgene Corporation has historically held a robust portfolio of patents surrounding lenalidomide (marketed as Revlimid). U.S. Patent 9,084,802 is one of several method-of-use patents. Other relevant patent families and exclusivities include:
- Core Compound Patents: Original patents covering the lenalidomide molecule itself, which have largely expired.
- Formulation Patents: Patents covering specific formulations of lenalidomide, such as crystalline forms or dosage forms.
- Additional Method-of-Use Patents: Patents covering other indications for lenalidomide, such as multiple myeloma, or different treatment regimens.
- Pediatric Exclusivity: Granted under the Pediatric Research Equity Act (PREA), which can extend market exclusivity for a drug if pediatric studies are conducted.
- Orphan Drug Exclusivity: For indications like MDS, orphan drug exclusivity can be granted, preventing approval of similar drugs for the same indication for a specified period (typically 7 years in the US).
Litigation and Challenges
Celgene has vigorously defended its lenalidomide patents against generic challenges. U.S. Patent 9,084,802 has been a subject of dispute.
- Inter Partes Review (IPR): Generic manufacturers have challenged the validity of Celgene's patents, including those related to lenalidomide, through IPR proceedings at the U.S. Patent and Trademark Office (USPTO). These challenges aim to invalidate patent claims based on prior art.
- District Court Litigation: Infringement lawsuits have been filed by Celgene against generic companies seeking to market their versions of lenalidomide. These cases often involve claims of direct infringement of method-of-use patents.
- Key Litigation Outcomes: Decisions in these cases have varied. Some challenges have led to the invalidation of certain patent claims, while others have upheld patent validity. The outcome of these legal battles significantly impacts the timeline for generic market entry.
For instance, in disputes concerning Revlimid, courts have had to interpret the scope of method-of-use claims and whether generic prescribing information would induce infringement. Generic manufacturers typically seek to include "skinny labels" that carve out patented indications to avoid direct infringement. However, the broadness of method claims like those in U.S. Patent 9,084,802 can complicate this strategy.
Generic Entry and Market Dynamics
The patent expiration and the outcomes of litigation directly influence the availability and pricing of lenalidomide generics.
- Generic Entry Timeline: The timeline for generic lenalidomide entry has been significantly shaped by patent litigation and settlement agreements. While the compound patent may have expired, the method-of-use patents and their enforceability have created a prolonged period of market exclusivity for the branded product.
- Impact on Pricing: The introduction of generics typically leads to a substantial decrease in drug prices due to increased competition. This has a direct impact on healthcare costs and patient access.
- Competition: Beyond generic lenalidomide, the MDS treatment landscape includes other therapeutic agents. While U.S. Patent 9,084,802 is specific to lenalidomide, other approved therapies for MDS, such as hypomethylating agents (e.g., azacitidine, decitabine) and other supportive care treatments, represent the broader competitive environment. However, the claims of U.S. Patent 9,084,802 are narrowly focused on a specific lenalidomide regimen.
The strategic importance of U.S. Patent 9,084,802 lies in its role as a potential barrier to entry for generic lenalidomide, particularly for the specific treatment regimen it covers for MDS. Companies seeking to develop or market generic lenalidomide must carefully navigate this patent, assessing its validity and potential infringement.
What Are the Key Takeaways?
- U.S. Patent 9,084,802 protects specific methods of treating myelodysplastic syndromes (MDS) using lenalidomide, particularly a 10 mg daily dosage for at least 21 consecutive days, with claims extending to dosage escalations and specific patient populations.
- The patent's scope is defined by its method-of-use claims, not the lenalidomide compound itself, creating a nuanced challenge for generic manufacturers who must avoid inducing infringement of these specific treatment protocols.
- The patent landscape is characterized by a history of extensive litigation, including inter partes reviews and district court battles, aimed at challenging the validity of Celgene's lenalidomide patents.
- Outcomes of these legal challenges have significantly influenced the timeline for generic lenalidomide market entry and the pricing dynamics of the drug.
Frequently Asked Questions
-
Does U.S. Patent 9,084,802 cover lenalidomide itself?
No, U.S. Patent 9,084,802 is a method-of-use patent. It does not claim the lenalidomide molecule itself but rather specific methods of treating myelodysplastic syndromes with lenalidomide.
-
What specific patient group is emphasized in the claims of U.S. Patent 9,084,802?
The patent claims emphasize patients diagnosed with myelodysplastic syndromes, with specific focus on those with a del(5q) chromosomal abnormality. It also includes claims for treatment-naive patients and those not previously treated with erythropoiesis-stimulating agents.
-
What is the typical duration and dosage regimen protected by the core claims?
The core claims often specify a daily dosage of 10 mg of lenalidomide administered for at least 21 consecutive days, with further claims extending to dosage escalations to 15 mg and defined durations for subsequent treatment phases.
-
How does this patent affect generic lenalidomide availability?
This patent, as a method-of-use patent, can prevent generic manufacturers from marketing lenalidomide for the specific indications and regimens claimed without infringing the patent, unless the patent is successfully challenged or invalidated.
-
What are the criteria for "disease progression" or "significant reduction in transfusion requirements" as defined in the patent?
The patent defines disease progression by specific increases in blast percentage or sustained decreases in hemoglobin. Significant reduction in transfusion requirements is quantified as a decrease of at least 4 units of packed red blood cells over an 8-week period.
Citations
[1] Celgene Corporation. (2015). United States Patent 9,084,802: Lenalidomide treatment of myelodysplastic syndromes. U.S. Patent and Trademark Office.
[2] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website].
[3] U.S. Patent and Trademark Office. (n.d.). Patent Trial and Appeal Board (PTAB) Decisions. Retrieved from [USPTO PTAB website].
[4] Legal databases and dockets (e.g., PACER, LexisNexis, Westlaw) for specific patent litigation case information related to Revlimid and Celgene Corporation.
More… ↓
⤷ Start Trial
|
